Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia

Abstract

BackgroundDysregulation of circulating miR-328 has been identified in several tumors and is associated with prognosis of patients. However, the expression pattern of miR-328 and the impact on prognosis has not yet been studied in acute myeloid leukemia (AML). The purpose of this study is to investigate the expression status of miR-328 and its clinical significance in AML patients.MethodsRNA was extracted from plasma of 176 patients with newly diagnosed AML and 70 healthy volunteers. The miR-328 expression was examined by Realtime quantitative PCR. The association of circulating miR-328 expression with clinicopathological factors and prognosis of AML patients was statistically analyzed.ResultsThe expression of miR-328 was significantly downregulated in AML patients (median value 22.99, range: 3.63-242.0) compared with those of healthy controls (median value 89.17, range: 12.05-397.7; P < 0.001), and miR-328 expression was markedly increased in patients after treatment than before (23.40 ± 1.76 vs. 46.61 ± 3.83, P < 0.001). Moreover, low levels of miR-328 were associated with a higher white blood cell count and BM blast count (P = 0.026 and P = 0.003, respectively), and lower hemoglobin and platelet count (P = 0.004 and P = 0.022, respectively). Patients with low miR-328 expression had a relatively poor overall survival (P = 0.022) and shorter relapse-free survival (P = 0.008) than those with high miR-328 expression. In addition, low miR-328 expression was an independent prognostic factors for both OS (P = 0.017) and RFS (P = 0.023).ConclusionsCirculating miR-328 downregulation is a common event and is associated with poor clinical outcome in AML patients.

Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia

“…Diaz-Beya et al reported that high miR-3151 expression was commonly found in AML patients and obtained shorter disease-free, OS, lower CR rate and higher cumulative incidence of relapse compared with low expressers [67]. The underexpression of miR-328 in AML patients had poor clinical outcome and may provide a diagnostic and prognostic biomarker [68]. MiR-34a expression was negatively correlated with aggressive clinical variable.…”

LINC00210 plays oncogenic roles in non‑small cell lung cancer by sponging microRNA‑328‑5p

“…In nasopharyngeal carcinoma, miR-328 is considered as a potential prognostic and therapeutic marker due to its inhibiting effect on the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells (26). Liu et al (27) demonstrated that low miR-328 expression can predict a poor prognosis in patients with acute myeloid leukemia. Previous studies also reported that low miR-328 expression level is associated with poor survival in patients with high-grade glioma, and that miR-328 can impair glioma cell proliferation and invasive ability.…”

CIRCULATING microRNA EXPRESSION IN MYELODYSPLASTIC SYNDROME

“…Tako je profil izražaja miRNK u RAEB-1 (refraktorna anemija s viškom blasta tipa I) bio sličan izražajima kod IPSS-a niskog rizika, dok je profil izražaja miRNK pri MDS-u RAEB-2 (refraktorna anemija s viškom blasta tipa II) pokazao sličnost s onime u bolesnika s AML-om. [34][35][36] Jedna od studija koje su pokušale povezati izražaj različitih miRNK s poznatim prognostičkim parametrima uključila je 44 bolesnika s MDS-om i definirala 68 miRNK koji su bili različitog izražaja među bolesnicima s MDS-om visokog rizika i s onime niskog rizika. Izdvojen je miRNK-181b koji je bio pojačano izražen u obje grupe, ali je njegov pojačani izražaj u grupi s MDS-om niskog rizika bio povezan s kraćim preživljenjem.…”